T​he vast US payout may reshape teen safety online​ beyond the borders of America, but there are more lawsuits to come ...

When a major tech company introduces a brand-new operating system or platform architecture, the hardware playbook is usually ...

Since adding the Google Fitbit Air to my arsenal, I've been wearing it almost all the time. The only times I forgot to strap it on were a night or two when I left it on the charging puck because I was ...

I tested the best audio streaming services, from Apple Music to Spotify, to see which most deserves your monthly subscription ...

Ultra-secure encryption algorithm added to ISO standard for Asymmetric Ciphers Classic McEliece is first PQC algorithm to achieve global standardization Organisations in 177 ISO member states can now ...

Quispe López is the lifestyle and health editor equalpride and an LGBTQ+ issues journalist whose work has appeared in NOLA.com | The Times-Picayune and Business Insider. As a transmasculine Quechua ...

Instagram is expanding its Your Algorithm feature to the main feed, enabling users to view and modify the topics that drive their content recommendations The update utilizes large language models to ...

The equity risk premium has effectively vanished. While it is a signal worth heeding, it is not cause for immediate alarm, particularly for portfolios that are genuinely diversified. In recent weeks ...

In 2023, the Federal Trade Commission, then led by Joe Biden appointee Lina Khan, along with 17 states, filed an antitrust lawsuit against Amazon. The case, finally scheduled to go to trial next year, ...

What’s unusual today is the degree of divergence between individual stocks and the cap-weighted index. The single most damaging decision most investors make during periods of falling stock market ...

Google's John Mueller said that when it comes to AI Search and the changes that come with that, Google's core search algorithms, spam detection methods, spam policies, and other search systems do not ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...